{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:02:49Z","timestamp":1711112569597},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,25]]},"DOI":"10.7759\/cureus.15238","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T15:43:53Z","timestamp":1621957433000},"source":"Crossref","is-referenced-by-count":1,"title":["The Use of Clozapine in the Serious Mental Illness Patients Enrolled in an Assertive Community Treatment Program"],"prefix":"10.7759","author":[{"given":"Maria Ruiza","family":"Yee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Espiridon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeolu  O","family":"Oladunjoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udema","family":"Millsaps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nailah","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish H","family":"Vora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Institute of Mental Health. Mental illness. (2021). Accessed. April 14, 2021: https:\/\/www.nimh.nih.gov."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14490","article-title":"The use of long-acting injectable antipsychotics (LAI) in the serious mental illness (SMI) patients enrolled in an assertive community treatment (ACT) program","volume":"13","author":"Yee MR","year":"2021","unstructured":"Yee MR, Espiridon E, Oladunjoye AO, Millsaps U, Vora A, Harvey N. The use of long-acting injectable antipsychotics (LAI) in the serious mental illness (SMI) patients enrolled in an assertive community treatment (ACT) program. Cureus. 2021, 13:e14490. 10.7759\/cureus.14490","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08030366","article-title":"Assessing the economic costs of serious mental illness","volume":"165","author":"Insel TR","year":"2008","unstructured":"Insel TR. Assessing the economic costs of serious mental illness. Am J Psychiatry. 2008, 165:663-5. 10.1176\/appi.ajp.2008.08030366","journal-title":"Am J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440-1665.2005.02175.x","article-title":"Assertive community treatment of the mentally ill: service model and effectiveness","volume":"13","author":"Udechuku A","year":"2005","unstructured":"Udechuku A, Olver J, Hallam K, et al.. Assertive community treatment of the mentally ill: service model and effectiveness. Australas Psychiatry. 2005, 13:129-34. 10.1080\/j.1440-1665.2005.02175.x","journal-title":"Australas Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.6.771","article-title":"Moving assertive community treatment into standard practice","volume":"52","author":"Phillips SD","year":"2001","unstructured":"Phillips SD, Burns BJ, Edgar ER, et al.. Moving assertive community treatment into standard practice. Psychiatr Serv. 2001, 52:771-9. 10.1176\/appi.ps.52.6.771","journal-title":"Psychiatr Serv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1176\/ps.46.7.669","article-title":"Assertive community treatment: an update of randomized trials","volume":"46","author":"Burns BJ","year":"1995","unstructured":"Burns BJ, Santos AB. Assertive community treatment: an update of randomized trials. Psychiatr Serv. 1995, 46:669-75. 10.1176\/ps.46.7.669","journal-title":"Psychiatr Serv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00115677-200109030-00003","article-title":"Assertive community treatment for people with severe mental illness","volume":"9","author":"Bond GR","year":"2001","unstructured":"Bond GR, Drake RE, Mueser KT, et al.. Assertive community treatment for people with severe mental illness. Dis Manage Health Outcomes. 2001, 9:141-59. 10.2165\/00115677-200109030-00003","journal-title":"Dis Manage Health Outcomes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/070674379904400504","article-title":"Economic impacts of assertive community treatment: a review of the literature","volume":"44","author":"Latimer EA","year":"1999","unstructured":"Latimer EA. Economic impacts of assertive community treatment: a review of the literature. Can J Psychiatry. 1999, 44:443-54. 10.1177\/070674379904400504","journal-title":"Can J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1037\/h0080329","article-title":"Intersite variation in the impact of intensive psychiatric community care on hospital use","volume":"68","author":"Rosenheck R","year":"1998","unstructured":"Rosenheck R, Neale M. Intersite variation in the impact of intensive psychiatric community care on hospital use. Am J Orthopsychiatry. 1998, 68:191-200. 10.1037\/h0080329","journal-title":"Am J Orthopsychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis SW","year":"2006","unstructured":"Lewis SW, Barnes TR, Davies L, et al.. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006, 32:715-23. 10.1093\/schbul\/sbj067","journal-title":"Schizophr Bull"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy JP","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, et al.. Effectiveness of clozapine versus olanzapine, quetiapine, risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment . Am J Psychiatry. 2006, 163:600-10. 10.1176\/appi.ajp.163.4.600","journal-title":"Am J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.110.88690","article-title":"Clozapine: dangerous orphan or neglected friend?","volume":"198","author":"Farooq S","year":"2011","unstructured":"Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend?. Br J Psychiatry. 2011, 198:247-9. 10.1192\/bjp.bp.110.88690","journal-title":"Br J Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003","volume":"30","author":"Lehman AF","year":"2004","unstructured":"Lehman AF, Kreyenbuhl J, Buchanan RW, et al.. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004, 30:193-217. 10.1093\/oxfordjournals.schbul.a007071","journal-title":"Schizophr Bull"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane J","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988, 45:789-96. 10.1001\/archpsyc.1988.01800330013001","journal-title":"Arch Gen Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112443744","article-title":"Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial","volume":"26","author":"Hermes E","year":"2012","unstructured":"Hermes E, Rosenheck R. Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. J Psychopharmacol. 2012, 26:1194-200. 10.1177\/0269881112443744","journal-title":"J Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033333","article-title":"Management of the adverse effects of clozapine","volume":"24","author":"Young CR","year":"1998","unstructured":"Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998, 24:381-90. 10.1093\/oxfordjournals.schbul.a033333","journal-title":"Schizophr Bull"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"337","author":"Rosenheck R","year":"1997","unstructured":"Rosenheck R, Cramer J, Xu W, et al.. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997, 337:809-15. 10.1056\/NEJM199709183371202","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1999.tb07225.x","article-title":"Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy","volume":"99","author":"Percudani M","year":"1999","unstructured":"Percudani M, Fattore G, Galletta J, Mita PL, Contini A, Altamura AC. Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy. Acta Psychiatr Scand. 1999, 99:274-80. 10.1111\/j.1600-0447.1999.tb07225.x","journal-title":"Acta Psychiatr Scand"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-007-0142-y","article-title":"Clinicians' reasons for deviations from recommended dosing practices for antipsychotic medications","volume":"34","author":"Sernyak MJ","year":"2007","unstructured":"Sernyak MJ, Rosenheck R. Clinicians' reasons for deviations from recommended dosing practices for antipsychotic medications. Adm Policy Ment Health. 2007, 34:540-7. 10.1007\/s10488-007-0142-y","journal-title":"Adm Policy Ment Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/57875-the-use-of-clozapine-in-the-serious-mental-illness-patients-enrolled-in-an-assertive-community-treatment-program","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:08Z","timestamp":1707507248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/57875-the-use-of-clozapine-in-the-serious-mental-illness-patients-enrolled-in-an-assertive-community-treatment-program"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.15238","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}